FindTrial
Sign In

Understanding the role of genetic variants in migraine: A study on immune pathways in the Indian population

Multifaceted investigation of NFAT and FOXP3 genetic variants in migraine susceptibility A combined genome wide association study and immune profiling pathway approach in an Indian population - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/04/084244
Enrollment
556
Registered
2025-04-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G439- Migraine, unspecified

Interventions

Control Intervention1: NIL: NIL

Sponsors

SRM Institute of Science and Technology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Migraine patients diagnosed according to the International Classification of Headache Disorders criteria 2.Adults aged 18 to 55 years. 3.Includes both episodic and chronic migraine patients. 4. more than 1 migraine attacks per month. 5.Willing to participate and provide informed consent.

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating individuals. 2.Recent use of immunosuppressive therapy. 3.Comorbid neurological or immune disorders 4.Participants with a history of substance abuse or alcohol dependence 5.Recent participation in another clinical study or clinical trial (within 3 months). 6.History of severe allergies or hypersensitivity reactions to blood collection procedures. 7.Presence of psychiatric disorders (e.g., major depression, schizophrenia)

Design outcomes

Primary

MeasureTime frame
1. Identify SNPs in NFAT and FOXP3 associated with migraine susceptibility in an Indian population using GWAS. 2. Identify immune cells (Tregs - CD4+CD25+FOXP3+, T cells CD28 & Th17) and quantify the expression of key transcription factors (NFATc1, NFATc2, and NFKB1(p50)) involved in neuroinflammation and immune dysregulation in migraine patients using flow cytometry. 3. Quantify serum cytokine levels in migraine patients compared to healthy controls using ELISA.Timepoint: Investigation of 3 to 6 months—

Secondary

MeasureTime frame
1.Investigate hereditary patterns of migraine in the Indian population through family-based analysis. 2.Assess whether specific NFAT & FOXP3 variants contribute to migraine severity, frequency, or chronicity. 3.Identify genetic & immunological markers that could serve as potential biomarkers for improved migraine diagnosis & targeted treatments. Timepoint: Investigation of 3 months—

Countries

India

Contacts

Public ContactMs Subalakshmi Sugumar

SRM College of Pharmacy, SRM Institute of Science and Technology

chitrav@srmist.edu.in9444459620

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026